DOCSLIB.ORG

Myeloma for Diagnosticians

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Myeloma for Diagnosticians Myeloma for Diagnosticians Dr Mamta Garg Consultant Haematologist What is Myeloma? Malignant disorder of plasma cells • an excess of abnormal plasma cells >10% • paraprotein in the serum and/or urine • End organ affection CRAB, SLiM CRAB Diagnosis: Paraprotein or M protein SPEP CRAB and now “Slim CRAB” • Myeloma defining events or Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: – C: Hypercalcaemia: serum calcium >0·25 mmol/L higher than the upper limit of normal or >2·75 mmol/L R: Renal insufficiency – R: Creatinine clearance <40 mL per min or serum creatinine >177 μmol/L (>2 mg/dL) – A: Anaemia: Hb >20 g/L below usual Hb, or a Hb <100 g/L – B: Bone lesions: one or more osteolytic lesions on XR, CT or PET-CT • Any one or more of the following biomarkers of malignancy: – S (M-spike) : Clonal bone marrow plasma cell percentage* ≥60% – Li: Involved:uninvolved serum free light chain ratio≥100 (or <0.01) – M: >1 focal lesions on MRI studies of 1 cm in size Rajkumar et al. Lancet Oncol. 2014 Nov;15(12):e538-48 Asymptomatic/Smouldering Myeloma • M protein present in serum and/or urine • Plasma cells >10% in the marrow • No CRABs • It carries a higher risk of progression to frank multiple myeloma (10% per year the first 5 years) compared with MGUS ISS, now Revised ISS or R-ISS LDH and FISH analysis on BM sample mandatory ISS STAGE CRITERIA RISK CRITERIA I B2M <3.5 Albumin >35 Normal Normal Serum LDH <upper limit of normal II B2M >3.5 but <5.5 or Albumin <35 High High serum LDH >255 for us III B2M >5.5 R-ISS STAGE CRITERIA I ISS I and standard risk cytogenetic abnormality and RISK CRITERIA normal LDH Standard No high risk chromosomal II Not R-ISS I or III abnormalities (CA) III ISS stage IIIand either high risk High Risk T(4:14), t(14:16) del 17p Iq CA by iFISH or high LDH gains, Ip loss and t(16:20) IMWG report Palumbo et al JCO Aug 3 2015 61 2267 Munshi et al IMWG panel 2 consensus recommendations for risk stratification Blood 2011 117 4696 -4700 R-ISS risk stratify and helps to prognosticate ISS CA High R-ISS PFS m OS m Non Tx Tx iMiD PI LDH based I No No I 66 NR 66 NR NR NR I Y/N Y/N II 42 83 70 88 88 81 (8 yrs) II II 42 83 70 88 88 81 III y/N Y/N III 29 43 41 42 40 47 (3.5 y) IMWG report Palumbo et al JCO Aug 3 2015 61 2267 Munshi et al IMWG panel 2 consensus recommendations for risk stratification Blood 2011 117 4696-4700 Age-specific incidence rates by age group for myeloma in males and females between 2006-2008 in England NCIN. Haematological malignancies in England 2001-2008 Demographics • Myeloma is a disease of the elderly • In UK median age at diagnosis 73 years • Latest USA registry data: 55% are ≥ age 75 (1975-2010) • More and more patients >87 years • Incidence: 65-70 new symptomatic cases per year in Leicester (68/million) • Additional 10 Asymptomatic myeloma per year Changing demographics • Incidence and prevalence of myeloma expected to rise – Aging population predicted increased incidence of 57% between 2010-2030 – Better GP and medical education, high index of suspicion leads to earlier diagnosis – Improved survival with novel therapies from 3.5 years to 10 years • therefore increased prevalence – Disease biology is different in very elderly myeloma – sometimes responds to dexamethsone alone giving patients survival of >12m – it is difficult to tell clinicians not to test/diagnose over 90 – Treated up to 97 years of age with steroids alone above 90 years age Natural course of disease 1st line 2nd line 3rd line treatment treatment treatment MGUS: Monoclonal gammopathy of undetermined significance Survival improving Shahjikumar Leukemia(2017) 1915–1921 Presentation • De novo or following MGUS - <5% • Bone problems – Back pain – Spinal cord compression – Pathological fracture • Renal Failure • Recurrent infections • Anaemia….often macrocytic • Chance finding…............ACR:PCR discrepancy on diabetic review Who diagnoses/suspect Myeloma in Leicestershire • 90 consecutive NDMM patients assessed – symptomatic • 33 from GP – 20 backache – 17 anaemia – 3 high ca – 4 AKI – 2 urine PCR and ACR discrepancy • 34 from medics: a/w high ca, full house, AKI, anaemia, sepsis, radiology flag, skeletal lesions • 12 Renal team with AKI and Igs is part of workup • 5 radiology flag • 3 spinal surgeon/orthopaedics • 3 from MGUS or AMM monitoring – raises concern over monitoring practices Presentation • Back pain is the 2 nd most common complaint in primary care • <1% of patients presenting with back pain will have a malignant cause • Back pain is the most common complaint in myeloma presentation (58%) • Anaemia and any other abnormal blood parameter with back pain was highly predictive of ‘high risk’ back pain • Average 11 months Time to diagnose from various pointers in blood test J Am Board Fam Med November-December 2016 vol. 29 no. 6 702-709 Immunoglobulin molecule Light chains are small molecules Kappa ~ 25kDa Lambda ~ 50 kDa Can pass through GBM, reabsorbed and metabolised in proximal convoluted tubules Capacity up to 500 mg/day In Myeloma if the light chains are produced in excess then the capacity to be reabsorbed in PCT is overcome and Light chains appear in urine (Bence Jones Proteinuria) Urine protein and albumin • Normally there should be no protein in the urine. • Particles with a molecular mass of >60kDa cannot filter through the glomerular basement membrane (GBM) • Albumin is 66.5 kDa cannot filter through glomerulus unless there is a structural damage to the glomeruli for ex in diabetic nephropathy • Commonly found proteins in the urine are • Albumin in disease state in glomerular diseases • free light chains in myeloma/MGUS (also called urinary bence jones UBJ) • haemoglobin or myoglobin in specific disease states • B2 Microglobulin • Normal tubular protein like tams-horsfall protein <0.15 g/d • Total urinary protein excretion in the normal adult < 150mg/day • Total Albumin excretion should be < 30mg/day. • http://bestpractice.bmj.com/best-practice/monograph/875.html Urine PCR and ACR – usual report • Normal Levels • Urine PCR 0-30 mg/mmol • Urine ACR 0-2.5 mg/mmol creatinine • Urine Protein < 0.15 g/L • Urine Albumin 0-15 mg/L • PCR is raised in both BJ proteinuria as well as Albuminuria • ACR is only raised in albuminuria • Normally they are concordant as commonest disease state is albuminuria like in diabetes • When discordant then alarm bells should be ringing for myeloma • Like .. Case History to illustrate SB, 71 years female, presented with free light chain myeloma in June 2014 Free lambda on SPEP electrophoresis was 9.1 g/L (normal no band) Free lambda on serum freelite assay was 23,660 mg/L (normal range 5.7- 26.3) Her Urine PCR and ACR and serum creatinine in the preceding 2 years were as follows: 09/06/14 30/09/13 21/08/12 Urine PCR (0-30) 1312 1317 476 Urine ACR (0-2.5) 16.3 10.7 Urine Protein (<0.15) 5.51 g/L 6.32 g/L 3.62 g/L Urine albumin (0-15) 78 mg/L 81 mg/L Hb (115-160) 89 g/L Not done Not done Serum Creatinine (60-120) 403 mmol/L 58 77 Local data collection and analysis 100 consecutive patients with newly diagnosed myeloma who presented from July 2014 to July 2016 • Urine PCR and ACR, • Urine BJ positivity, • serum freelite levels • Presence or absence of renal impairment at diagnosis Results • Urine BJ negative in 29 patients – 100% had serum freelite <250 mg/L denoting reduced or negligible renal risk – 83% had normal Urine ACR and PCR and serum creatinine – 17% had abnormal creatnine due to unrelated causes and not due to myeloma • Urine BJ was positive in 66 patients – Urine PCR was done in 48 patients – Normal PCR in 12 patients denoted negligible urine light chains or bence jones s/o low renal risk due to myeloma – Urine PCR was abnormal i.e. >30 mg/mmol in 36 patients. – PCR was x10 ACR in 27 patients (27 patients) who also had relatively higher serum freelite value >1000mg/L and were at maximum renal risk. • In 14 patients urine ACR and PCR were available from before, Urine PCR was >30 and 2 x ACR value several months prior to diagnosis. • PCR was 10 x ACR in 8 of these patients suggested that myeloma could have been diagnosed many months earlier as shown in examples above. Follow up action after the study/audit • Biochemistry department will insert a comment “If PCR is raised i.e. >30 mg/mmol and > twice the value of ACR, please send a urine sample to immunology for Bence Jones (light chains) proteinuria” • GP newsletter was sent out in September 2016 emphasise the need to interpret the results of Urine PCR and ACR correctly and to request screening tests for myeloma i.e. urine Bence Jones protein early. • Earlier diagnosis of myeloma will eventually result in reduced rates of complications, reduced morbidity and improved overall survival • GP are understanding results of Urine ACR and PCR better and are asking for Urine BJ earlier. Other unusual ways of diagnosing myeloma • Panhypogammaglobulinaemia • Macrocytic anaemia – unexplained • Hyponatraemia (pseudo) • Hyperphosphatemia (pseudo) • High total protein but low albumin • Changes in Immunology lab – if a pp is detected automatically do serum freelites since Jan 2017 • Not to miss 15% of light chain myelomas CM 55 years old male • Na 131, Creat 140, • Ca 2.49 PO 4 2.70 (0.8-1.5) • alb 26 glb x • Hb 83 • Lymph 4.33, we missed plasmacytoid eclls in circulation in the lab • 3 weeks later GP asked for Igs as he suspected myeloma • IgG 90.2 IgA <0.25 IgM <0.15 • PP 69.6 Assessment of a patient - NG35 • Bloods: UE, LFT, Bone, CRP, FBC, • Immunoglobulins/SPE and Serum
Load more

Recommended publications
  • Cytology of Myeloma Cells
    J Clin Pathol: first published as 10.1136/jcp.29.10.916 on 1 October 1976. Downloaded from J. clin. Path., 1976, 29, 916-922 Cytology of myeloma cells F. G. J. HAYHOE AND ZOFIA NEUMAN1 From the Department of Haematological Medicine, Cambridge University SYNOPSIS A cytological, cytochemical, and cytometric study of plasma cells from 195 cases of multiple myeloma showed that, contrary to earlier reports, flaming cells, thesaurocytes, and intra- nuclear inclusions are not confined to IgA-secreting cases but are common also in IgG and Bence Jones varieties of myeloma. IgA-secreting cells are not larger, nor do they have a lower nuclear- cytoplasmic ratio than other myeloma cells. On average, for a given mass of tumour, Bence-Jones, IgG, and IgA varieties of myeloma produce amounts of paraprotein in the ratio 1 to 1 6 to 2-7. In 1961 Paraskevas et al reported a correlation the results of a larger scale survey carried out some between the morphological features of plasma cells years ago but previously unpublished. in myeloma and the type of immunoglobulin secreted. The cases studied included 12 with y1A Material and methods (f2A, IgA) myeloma, 30 with y (IgG) myeloma, and six myelomas without M protein (probably Bence The study was performed on bone marrow smearscopyright. Jones myelomas). Flaming cells, thesaurocytes, and from 200 consecutive patients newly entered into a intranuclear, PAS-positive inclusion bodies were comparative trial of treatments in myeloma, under found only in cases of IgA myeloma, and flaming the auspices of the Medical Research Council. Five cells especially were present in most cases and in patients were subsequently excluded as not confirmed high percentage in several.
    [Show full text]
  • Evidence-Based Practice Center Systematic Review Protocol
    Evidence-based Practice Center Systematic Review Protocol Project Title: Serum-Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias I. Background and Objectives for the Systematic Review Plasma cell dyscrasias (PCDs) are a spectrum of disorders characterized by the expansion of a population of monoclonal bone-marrow plasma cells that produce monoclonal immunoglobulins.1 At the benign end of the spectrum is monoclonal gammopathy of undetermined significance (MGUS), where the plasma-cell clone usually does not expand. Multiple myeloma (MM) is a plasma cell disorder at the malignant end of the spectrum and is characterized by the neoplastic proliferation of a clone of plasma cells in the bone marrow with resulting end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal insufficiency. Whereas monoclonal plasma cells generally secrete intact immunoglobulin, in about 20 percent of patients with MM these cells only produce light-chain monoclonal proteins (i.e., light-chain multiple myeloma [LCMM], formerly known as Bence Jones myeloma) and in 3 percent of patients they secrete neither light- nor heavy-chain monoclonal proteins that are detectable by immunofixation (i.e., nonsecretory multiple myeloma [NSMM]).1 In two-thirds of patients with NSMM, a monoclonal protein can be identified by the serum-free light chain (SFLC) assay. Patients with LCMM develop complications related to tissue deposition of light chains, including amyloidosis. Amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis seen in the United States and is characterized by a relatively stable, slow-growing plasma-cell clone that secretes light-chain proteins that form Table 1: Diagnostic criteria and clinical course of selected plasma cell dyscrasias (PCDs)2 Disorder Disease Definition Clinical Course Monoclonal gammopathy of .
    [Show full text]
  • Canine Multiple Myeloma
    Canine Multiple Myeloma Meredith Maczuzak, DVM; Kenneth S. Latimer, DVM, PhD; Paula M. Krimer, DVM, DVSc; and Perry J. Bain, DVM, PhD Class of 2003 (Maczuzak) and Department of Pathology (Latimer, Krimer, Bain), College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7388 Introduction Multiple myeloma or plasma cell myeloma, is a neoplasm of well- differentiated B cell lymphocytes typically originating from the bone marrow. Neoplastic cells can metastasize widely, having a predilection for bone and resulting in osteolysis. The malignant transformation of a single B cell can secrete a homogenous immunoglobulin product known as paraprotein, which will mimic the structure of normal immunoglobulins. Overabundant production of paraprotein, consisting of any of the immunoglobulin classes, will appear as a sharp, well-defined peak or monoclonal gammopathy on serum electrophoresis. The most frequently encountered multiple myelomas secrete IgG or IgA paraproteins, however IgM myelomas (macroglobulinemia) have also been diagnosed in companion animals. Light chain disease is caused by plasma cell overproduction of the light chain segment of the immunoglobulin complex, consisting of either the lambda or kappa light chain. These proteins are referred to as Bence-Jones proteins and are the most commonly observed immunoglobulin fragments in the monoclonal gammopathies.2 There are rare instances where a malignant plasma cell neoplasm will be nonsecretory. These tumors occur in approximately 1% of all cases of multiple myeloma and are referred
    [Show full text]
  • Chapter 7: Hematologic Disorders and Kidney Disease
    Chapter 7: Hematologic Disorders and Kidney Disease Ala Abudayyeh, MD,* and Kevin Finkel, MD, FACP, FASN, FCCM*† *Division of General Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas; and †UTHealth Science Center at Houston Medical School, Department of Medicine, Division of Renal Diseases and Hypertension, Houston, Texas MULIPLE MYELOMA chains precipitate with Tamm-Horsfall protein (THP) secreted by the thick ascending limb of the Pathogenesis loop of Henle and produce casts in the distal tubule. Multiple myeloma (MM) is a hematologic malig- Decreased GFR may increase the concentration of nancy involving the pathologic proliferation of light chains in the distal tubule and enhance the terminally differentiated plasma cells. It is the formation of casts. Therefore, hypercalcemia, vol- second most common hematologic malignancy ume depletion, diuretics, and nonsteroidal anti- behind non-Hodgkin lymphoma, with an annual inflammatory drugs can exacerbate renal injury. incidence of 4–7 cases per 100,000 in the United In some cases of AKI associated with MM, cast States. Clinical symptoms are due to osteolysis of formation is rare on renal biopsy. Instead, renal the bone, suppression of normal hematopoiesis, injury is attributed to the direct toxic effects of and the overproduction of monoclonal immuno- urinary free light chains (FLCs) on proximal tubule globulins that deposit in organ tissues. Clinical cells (5,6). After reabsorption, lysosomal degrada- symptoms include bone pain and fractures, anemia, tion of FLCs can activate the NF-kB pathway lead- infections, hypercalcemia, edema, heart failure, and ing to oxidative stress with an inflammatory renal disease. response, apoptosis, and fibrosis.
    [Show full text]
  • Intranuclear Inclusions in Myeloma Patient
    Published online: 2021-05-24 Letter to Editor Pathologist’s Feast: Intranuclear Inclusions in Myeloma Patient Sir, aspiration [Figure 2]. Plasma cells showed Dutcher body We present a case of a 36‑year‑old female admitted in bone marrow aspiration [Figure 3] as periodic acid– in hospital with complaints of pain in sacral region Schiff positive intranuclear inclusion [Figure 4]. The bone radiating toward right lower limb for 1 month. Laboratory marrow biopsy showed loss of normal architecture with examination revealed hemoglobin 8.1 g/dL, red blood packed marrow studded by plasma cells [Figure 5]. cell count – 2.61 × 109/mm3, white blood cell count Multiple myeloma account for 1% of all cancers and 16.16 × 103/mm3, and platelet count 299 × 109/mm3. The approximately 10% of all hematological malignancies.[1] The differential showed polymorphs – 74%, lymphocytes – 22%, eosinophils – 1%, and monocytes – 3%. Peripheral blood peak incidence is seventh decade, and it is quite rare, below smear showed rouleaux formation in red blood cells. The 40 years of age. The clinical and biological characteristics serum biochemistry showed blood urea – 54 mg/dl and of multiple myeloma in young patients are similar to those [2] creatinine – 3.8 mg/dl, angiotensin converting enzyme in elderly as in literature in studies by Usha et al. and [3] level – 64.25 U/L, and serum calcium – 13.3 mg/dl. Liver Bladé et al. The above case shows ditcher body inclusions function tests and serum electrolytes were normal and in plasma cells on bone marrow aspiration. HIV and HBsAg were nonreactive.
    [Show full text]
  • Successful Autologous Peripheral Blood Stem Cell Harvest and ­Transplantation After Splenectomy in a Patient with Multiple ­Myeloma with Hereditary Spherocytosis
    International Journal of Myeloma 8(3): 11–15, 2018 CASE REPORT ©Japanese Society of Myeloma Successful autologous peripheral blood stem cell harvest and transplantation after splenectomy in a patient with multiple myeloma with hereditary spherocytosis Daisuke FURUYA1,4, Rikio SUZUKI1,4, Jun AMAKI1, Daisuke OGIYA1, Hiromichi MURAYAMA1,2, Hidetsugu KAWAI1, Akifumi ICHIKI1,3, Sawako SHIRAIWA1, Shohei KAWAKAMI1, Kaito HARADA1, Yoshiaki OGAWA1, Hiroshi KAWADA1 and Kiyoshi ANDO1 Hereditary spherocytosis (HS) is the most common inherited red cell membrane disorder worldwide. We herein report a 58-year-old male HS patient with mild splenomegaly who developed symptomatic multiple myeloma (MM). Autologous stem cell transplantation (ASCT) was considered to be adopted against MM, although there was a possibility of splenic rupture following stem cell mobilization. Therefore, splenectomy was performed prior to stem cell harvest, and he was able to safely mobilize sufficient CD34+ cells with G-CSF and plerixafor and undergo ASCT. This case suggests that stem cell mobilization after splenectomy is safe and effective in HS patients complicated with malignancies. Key words: multiple myeloma, hereditary spherocytosis, splenectomy, autologous peripheral blood stem cell harvest Introduction Consolidation with melphalan-based HDT followed by ASCT is still the standard treatment option for transplant-eligible Multiple myeloma (MM) is characterized by clonal prolifera- patients with MM, leading to higher complete response rates tion of abnormal plasma cells in the bone marrow (BM) micro- and increased progression-free survival and overall survival environment, monoclonal protein in the blood and/or urine, compared with conventional chemotherapy regimens [2]. bone lesions, and immunodeficiency [1]. In recent years, the Importantly, the emergence of novel agent-based therapy introduction of high-dose chemotherapy (HDT) and autol- combined with ASCT has revolutionized MM therapy [2].
    [Show full text]
  • Clinical Hematology 1
    CLINICAL HEMATOLOGY 1 CLINICAL HEMATOLOGY Editor Gamal Abdul Hamid, MD,PhD Associate Professor Faculty of Medicine and Health Sciences University of Aden CLINICAL HEMATOLOGY 2 PREFACE Clinical Hematology, first edition is written specifically for medical students, the clinician and resident doctors in training and general practioner. It is a practical guide to the diagnosis and treatment of the most common disorders of red blood cells, white blood cells, hemostasis and blood transfusion medicine. Each disease state is discussed in terms of the pathophysiology, clinical and paraclinical features which support the diagnosis and differential diagnosis. We bring together facts, concepts, and protocols important for the practice of hematology. In addition this book is also supported with review questions and quizzes. G.A-H 2012 CLINICAL HEMATOLOGY 3 CONTENTS Preface 1. Hematopoiesis 7 2. Anemia 26 3. Iron Deficiency Anemia 32 4. Hemolytic Anemia 41 5. Sickle Cell Hemoglobinopathies 49 6. Thalassemia 57 7. Hereditary Hemolytic Anemia 63 8. Acquired Hemolytic Anemia 68 9. Macrocytic Anemia 75 10. Bone Marrow Failure, Panctopenia 87 11. Spleen 95 12. Acute Leukemia 99 13. Chronic Myeloproliferative Disorders 125 14. Chronic Lymphoproliferative Disorders 137 15. Malignant Lymphoma 147 16. Multiple Myeloma and Related Paraproteinemia 171 17. Hemorrhagic Diseases 179 18. Transfusion Medicine 201 19. Bone Marrow Transplantations 214 CLINICAL HEMATOLOGY 4 Appendices: I. Hematological Tests and Normal Values 221 II. CD Nomenclature for Leukocytes Antigen 226 III. Cytotoxic Drugs 228 IV. Drugs Used in Hematology 230 Glossary 232 Answers 246 Bibliography 247 CLINICAL HEMATOLOGY 5 CLINICAL HEMATOLOGY 6 HEMATOPOIESIS 1 All of the cells in the peripheral blood have finite life spans and thus must be renewed continuously.
    [Show full text]
  • © 2016 First Aid for the USMLE Step 1
    Index A Abscess, 442 vs. aspirin, in pediatric patients, 446 Achondroplasia, 426 Abacavir, 184 Absence seizures, 494 free radical injury and, 221 autosomal dominance of, 71 for HIV, 186 drug therapy for, 500 necrosis caused by, 252 chromosome associated with, 75 Abciximab, 214, 407 treatments for, 638 for osteoarthritis, 430 endochondral ossification in, 425 thrombogenesis and, 385 Absolute risk reduction (ARR), 34, for tension headaches, 494 AChR (acetylcholine receptor), 229 Abdominal aorta, 342 646 toxicity effects, 446 Acid-base physiology, 543 atherosclerosis in, 286, 645 Absorption disorders, anemia caused toxicity treatment for, 251 Acidemia, 543 bifurcation of, 609 by, 388 Acetazolamide, 254, 557 diuretic effect on, 558 498 92 Abdominal aortic aneurysm, 286 Abuse for glaucoma, Acidic amino acids, metabolic acidosis caused by, 543 Acidosis, 543 Abdominal colic confidentiality exceptions and, 41 in nephron physiology, 537 contractility in, 267 lead poisoning as cause, 389 dependent personality disorder for pseudotumor cerebri, 471 hyperkalemia caused by, 542 Abdominal distension and, 519 site of action, 556 Acid phosphatase, in neutrophils, 378 duodenal atresia as cause, 338 Acalculia, 464 Acetoacetate, metabolism of, 102 Acid reflux Abdominal pain Acamprosate Acetone breath, in diabetic esophageal strictures and, 354 Budd-Chiari syndrome as for alcoholism, 523, 638 ketoacidosis, 331 esophagitis and, 354 cause, 368, 630 diarrhea caused by, 252 Acetylation, 57 H blockers for, 374 cilostazol/dipyridamole as Acanthocytes, 386 2 Acetylcholine
    [Show full text]
  • Open Full Page
    3IULTIPLE MYELOMA A REPORTOF FIVECASES ERNEST SCOTT, M.D., F. M. STANTON, M.D., AND MARY OLIVER, MA. (From the Department of Pathology, Ohio State University) In 1848 Sir Henry Bence-Jones aiid Sir James Watson pre- sented a paper entitled, “On a New substance Occurring in the Urine of a Patient with Mollitis-ossium,” a “substance” now known as the Bence-Jones bodies, frequeiitly found in the urine of patients with multiple myeloma. The clinical discussion of this same case mas presented in 1850 by McIntyre. In 1873 von Rustizky, in his histological studies of the disease, recognized its involvement of the bone marrow and gave it the name of multiple myeloma. IGililer, in 1889, ~lsopresented a clinical description of the disease and inasmuch as he, rather than McIntyre, has often been credited with the first clinical presentation, the term “Kahler ’s disease” is frequently encountered in the older litera- ture. In 1920 Wallgren reported 120 cases with histological verifica- tion. In 1928 Geschickter and Copeland (l), from the surgical pathological material of the Johns Hopkins Hospital, reported a series of 13 cases, together with a complete review of all available cases in the literature, making a total of 425 cases. Since the publication of this comprehensive article with its discussion of the clinical and structural characteristics of the disease, we have been able to collect from the more recent literature 30 cases of multiple myeloma. To these we add 5 cases from among about 4400 au- topsies in our own series. Grouped by years, the additional cases are : 1927 : Lewis (2), Meyeriling (3), Kleine (4) ; 1928: Battaglia (5), Hcilmann (6), Barr (7),Durman (8), Short iind Crawford (9) ; 1929: Hewitt (10) (5 cases), Stone (ll), Cappel1 (12) (2 cases), Rogers (13), Hub- bard and Case (14) ; 1930: Perla aiid Hutner (15) (2 cases), Cabot (16), Geschickter (17), Freund (18) ; 1931: Cabot (19), Porchownik (20), Jackson et a1 (21) (5 cases).
    [Show full text]
  • Pathology Course
    Pathology Course Kindly Sponsored by: Edited by: Michelle Kunc, Jhia Teh, Sally Barker and Yvonne Tsitsiou 1 Introduction The Medical Education Society (MedED) was established in 2004 by three students who were keen to develop schemes whereby senior students tutor younger ones - ‘peer-to- peer’ learning. It was decided that teaching would be outside the formal curriculum and the topics covered would reflect learning needs identified by members of the society and student body. This year we have coordinated PACES and Pathology revision courses, which are being delivered by past ICSM students. We hope you enjoy our Year 5 events and find their content useful for your revision. We would like to thank all the doctors involved in the production of this guide for their support and for taking time out of the schedules to come back and teach us. We would also like to thank the previous MedED guide editors: • 2016-2017: Daniel Campioni-Norman, Rhys Smith, Helen-Cara Younan and Rebekah Judge • 2017-2018: Charlie Caird, Stephanie EzeKwe, Mohammad Fallaha, Samyukta Sundar • 2018-2019: Sophia von Widekind, Lasith Ranasinghe, Daniel Huddart, Alex Huddart If you have any questions please contact us at [email protected]. Please note: MedED does not represent the ICSM Faculty or Student Union. This guide has been produced by students and the Pathology Course lecturers. We have made every effort to ensure that the following information is accurate and reliable. However, this guide should not be used to replace formal ICSM teaching and education
    [Show full text]
  • View the 2019 Index
    Index A Abnormal uterine bleeding (AUB), heart failure, 311 Achondroplasia, 454 A-a gradient 618, 619 hypertension, 319 chromosome disorder, 64 in elderly, 654 adenomyosis, 634 naming convention for, 253 endochondral ossification in, 450 with hypoxemia, 654, 655 anemia with, 410 preload/afterload effects, 282 inheritance, 60 restrictive lung disease, 661 Asherman syndrome, 634 teratogenicity, 600 AChR (acetylcholine receptor), 229 Abacavir, 201, 203 leiomyoma (fibroid), 634 Acetaldehyde, 72 Acid-base physiology, 580 Abciximab, 122 polyps (endometrial), 634 Acetaldehyde dehydrogenase, 70, 72 Acidemia, 580 Glycoprotein IIb/IIIa inhibitors, thecoma, 632 Acetaminophen, 474 diuretic effect on, 595 429 ABO blood classification, 397 vs. aspirin for pediatric patients, 474 Acid-fast oocysts, 177 thrombogenesis and, 403 newborn hemolysis, 397 free radical injury and, 210 Acid-fast organisms, 125, 140, 155 Abdominal aorta, 357 Abruptio placentae, 626 hepatic necrosis from, 249 Acidic amino acids, 81 atherosclerosis in, 305, 687 cocaine use, 600 N-acetylcysteine for overdose, 671 Acid maltase, 86 bifurcation of, 649 preeclampsia, 629 for osteoarthritis, 458 Acidosis, 578, 580 Abdominal aortic aneurysm, 306 Abscess, 470 toxicity effects, 474 contractility in, 282 Abdominal colic acute inflammation and, 215 toxicity treatment for, 247 hyperkalemia with, 578 lead poisoning, 411 lung, 670 Acetazolamide, 252, 539, 594 Acid phosphatase in neutrophils, 398 Abdominal pain Absence seizures idiopathic intracranial Acid reflux bacterial peritonitis, 384 characteristics
    [Show full text]
  • Bence Jones Proteins: Nature, Metabolism, Detection and Significance MICHAEL J
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 6, No. 1 Copyright @ 1976, Institute for Clinical Science Bence Jones Proteins: Nature, Metabolism, Detection and Significance MICHAEL J. DEEGAN, M.D. Clinical Immunology Laboratory, Department of Pathology, The University of Michigan Ann Arbor, MI 48104 ABSTRACT The nature of Bence Jones proteins is developed by a review of the pertinent literature. This is followed by a discussion of their metabolism and catabolism under normal and abnormal clinical conditions. Various methods for the detection of Bence Jones proteins are critically reviewed and the significance of these pro­ teins in various disorders is assessed. Nature more than a century after the initial descrip­ tion. In 1845 Henry Bence Jones, a physician The modern era of Bence Jones (BJ) pro­ and chemical pathologist at St. George’s tein analysis began with a report by Hospital in London, received a specimen of Edelman and Gaily16 that BJ proteins shared urine from Dr. Thomas Watson. The urine extensive antigenic cross-reactivity with was from a patient with an illness now myeloma proteins and normal gamma glob­ known to be multiple myeloma. Accom­ ulins. Putnam35 compared peptide maps of panying the specimen was a note the text of pooled human gamma globulin, seven which is reproduced here.11 purified pathologic globulins and eight BJ “The tube contains urine of very high proteins. On the basis of these studies, he specific gravity. When boiled it becomes concluded that there were two types of BJ highly opaque. On the addition of nitric acid protein and that they represented incom­ it effervesces, assumes a reddish hue and be­ plete or aberrant polypeptide chains of comes quite clear; but as it cools assumes the normal gamma globulin.
    [Show full text]